
    
      The study consists of two parts. The first part is double-blind, randomized and
      placebo-controlled. The second part has an open-label study design. In part 1 patients on
      Orkambi or other CFTR-modulators are excluded. In part 2 patients on Orkambi are allowed to
      be included under certain conditions.
    
  